IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Galectin Therapeutics Inc

CUSIP: 363225301 | 4 institutional holders

Quarters

Q3 2016Q2 2016Q1 2016Q4 2015Q3 2015
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q3 2016

UBS Group AG303
0.0% of portfolio›$1
StyleTurnoverLocationFiled
UBS Group AG
303$10.0%CoreMediumZurich, Switzerland2016-11-14